Provention Bio, Inc. PRVB
We take great care to ensure that the data presented and summarized in this overview for Provention Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PRVB
View allLatest Institutional Activity in PRVB
Top Purchases
Top Sells
About PRVB
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Insider Transactions at PRVB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 27
2023
|
Sessa Capital (Master), L.P. > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
15,567,497
-100.0%
|
-
|
|
Apr 27
2023
|
Ashleigh Palmer Director and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,570,050
-100.0%
|
-
|
|
Apr 27
2023
|
Wayne Pisano Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
7,500
-100.0%
|
-
|
|
Apr 27
2023
|
Francisco Leon Chief Scientific Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,500,000
-100.0%
|
-
|
|
Apr 27
2023
|
Francisco Leon Chief Scientific Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
73,000
-100.0%
|
-
|
|
Apr 27
2023
|
Eleanor Ramos Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
70,000
-100.0%
|
-
|
|
Apr 27
2023
|
Avery W Catlin Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
20,000
-100.0%
|
-
|
|
Apr 21
2023
|
Sessa Capital (Master), L.P. > 10% Shareholder |
SELL
Bona fide gift
|
Direct |
224,617
-100.0%
|
-
|
|
Apr 20
2023
|
Sessa Capital (Master), L.P. > 10% Shareholder |
SELL
Bona fide gift
|
Direct |
202,314
-47.39%
|
-
|
|
Apr 14
2023
|
Sessa Capital (Master), L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,190,549
-12.34%
|
$52,573,176
$24.32 P/Share
|
|
Apr 14
2023
|
Sessa Capital (Master), L.P. > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
8,879,023
+33.33%
|
$53,274,138
$6.0 P/Share
|
|
Apr 13
2023
|
Francisco Leon Chief Scientific Officer |
BUY
Bona fide gift
|
Indirect |
1,500,000
+95.36%
|
-
|
|
Apr 13
2023
|
Francisco Leon Chief Scientific Officer |
SELL
Bona fide gift
|
Direct |
1,500,000
-95.36%
|
-
|
|
Apr 13
2023
|
Avery W Catlin Director |
BUY
Bona fide gift
|
Indirect |
10,000
+50.0%
|
-
|
|
Apr 13
2023
|
Avery W Catlin Director |
SELL
Bona fide gift
|
Direct |
10,000
-50.0%
|
-
|
|
Apr 04
2023
|
Sessa Capital (Master), L.P. > 10% Shareholder |
SELL
Bona fide gift
|
Direct |
218,651
-33.87%
|
-
|
|
Mar 31
2023
|
Sessa Capital (Master), L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
3,000,000
-25.25%
|
-
|
|
Feb 13
2023
|
Francisco Leon Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,985
-1.63%
|
$259,850
$10.04 P/Share
|
|
Feb 13
2023
|
Francisco Leon Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,985
+1.6%
|
$51,970
$2.5 P/Share
|
|
Feb 13
2023
|
Ashleigh Palmer Director and CEO |
SELL
Open market or private sale
|
Direct |
25,835
-1.0%
|
$258,350
$10.04 P/Share
|